Drug Ther Bull. 2017 Nov;55(11):129-132. doi: 10.1136/dtb.2017.11.0553.
The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose-response with fixed doses and limited interactions with food and drugs. However, these agents have been in widespread clinical use for less than a decade and, compared with extensive experience with warfarin, there is uncertainty relating to optimal laboratory monitoring of anticoagulation, perioperative management and treatment of bleeding.3 In addition, there is currently only one drug licensed in the UK for rapid reversal of the anticoagulant effect of a DOAC. Here, we review DOAC-related bleeding and the role of drugs to reverse the anticoagulant action of DOACs.
直接口服抗凝剂（DOACs），也被称为新型（或非维生素K拮抗剂）口服抗凝剂（NOACs），因其起效迅速、固定剂量下剂量反应可预测以及与食物和药物的相互作用有限，成为抗凝治疗的一项重大进展。然而，这些药物在临床广泛使用尚不足十年，与华法林的丰富经验相比，抗凝的最佳实验室监测、围手术期管理和出血治疗方面仍存在不确定性。此外，目前在英国仅有一种药物被批准用于快速逆转DOAC的抗凝作用。在此，我们综述与DOAC相关的出血以及逆转DOAC抗凝作用的药物的作用。
